Arix Bioscience PLC (ARIX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

 


Get this Report



PayPal Verified Vendor

Rating

4.3 Star Rating for report Arix Bioscience PLC (ARIX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
4.3 / 5 stars rating
Pages: 35
Price: $250.00

Some of our Clients

Some Research and Expert Clients

Abstract

 
Arix Bioscience PLC (ARIX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
 

Description

Arix Bioscience PLC (Arix Bioscience), formerly Arix Bioscience Ltd, is a healthcare and life science company. It offers financing and operational and strategic direction for the companies to support their businesses. The company's expertise spans in various areas which include academic science, clinical and commercial strategy, company operations, venture capital, mergers and acquisitions and corporate finance. Arix Bioscience works in collaboration with universities in the UK, Europe and Australia for providing direct access to the innovative new technologies. It offers its services to both public and private sector companies. The company also has an operational presence in New York, the US. Arix Bioscience is headquartered in London, the UK. 

Report Source Information

Supplied by: Research and Experts 
Date Published: 2017-11-27 

Report: Arix Bioscience PLC (ARIX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

 

Contents

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Arix Bioscience PLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Arix Bioscience PLC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Arix Bioscience PLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Arix Bioscience PLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Arix Bioscience PLC, Medical Devices Deals, 2011 to YTD 2017 9
Arix Bioscience PLC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Arix Bioscience PLC, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Autolus Raises USD80 Million in Series C Financing 13
PreciThera Raises USD28.8 Million in Series A Financing 15
Amplyx Pharma Raises USD67 Million in Series C Financing 16
Mitoconix Bio Raises USD20 Million in Series A Financing 18
LogicBio Therapeutics Raises USD45 Million in Series B Financing 19
Harpoon Therapeutics Raises USD45 Million in series B Financing 20
Iterum Therapeutics Raises USD65 Million in Series B Venture Financing 21
Artios Pharma Raises USD33.2 Million in Series A Financing 23
OptiKira Raises Funds through Venture Financing 24
Partnerships 25
Arix Bioscience, Lead Discovery Center, Max Planck Innovation and University of Leeds Enter into Partnership 25
Licensing Agreements 26
Mitoconix Bio Enters into Licensing Agreement with Stanford University 26
Equity Offering 27
Arix Bioscience Completes Underwriter's Exercise of Over-Allotment Option of IPO for USD142 Million 27
Verona Pharma Raises USD63 Million in Private Placement of Units 28
Arix Bioscience PLC - Key Competitors 31
Arix Bioscience PLC - Key Employees 32
Arix Bioscience PLC - Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Recent Developments 34
Corporate Communications 34
Sep 04, 2017: Arix Bioscience notes the appointment of Dr Graeme Smith as CSO of Artios Pharma 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35
 

List of Tables

List of Tables
Arix Bioscience PLC, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Arix Bioscience PLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Arix Bioscience PLC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Arix Bioscience PLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Arix Bioscience PLC, Deals By Therapy Area, 2011 to YTD 2017 8
Arix Bioscience PLC, Medical Devices Deals, 2011 to YTD 2017 9
Arix Bioscience PLC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Autolus Raises USD80 Million in Series C Financing 13
PreciThera Raises USD28.8 Million in Series A Financing 15
Amplyx Pharma Raises USD67 Million in Series C Financing 16
Mitoconix Bio Raises USD20 Million in Series A Financing 18
LogicBio Therapeutics Raises USD45 Million in Series B Financing 19
Harpoon Therapeutics Raises USD45 Million in series B Financing 20
Iterum Therapeutics Raises USD65 Million in Series B Venture Financing 21
Artios Pharma Raises USD33.2 Million in Series A Financing 23
OptiKira Raises Funds through Venture Financing 24
Arix Bioscience, Lead Discovery Center, Max Planck Innovation and University of Leeds Enter into Partnership 25
Mitoconix Bio Enters into Licensing Agreement with Stanford University 26
Arix Bioscience Completes Underwriter's Exercise of Over-Allotment Option of IPO for USD142 Million 27
Verona Pharma Raises USD63 Million in Private Placement of Units 28
Arix Bioscience PLC, Key Competitors 31
Arix Bioscience PLC, Key Employees 32
Arix Bioscience PLC, Other Locations 33
Arix Bioscience PLC, Subsidiaries 33
 

List of Figures

List of Figures
Arix Bioscience PLC, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
Arix Bioscience PLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
Arix Bioscience PLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
Arix Bioscience PLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
Arix Bioscience PLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Arix Bioscience PLC, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
Arix Bioscience PLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Arix Bioscience PLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Arix Bioscience PLC, Medical Devices Deals, 2011 to YTD 2017 9
 

Scope


- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

 

Classification

Language Code: EN 
Region: United Kingdom 
Report Type: Company Reports 
Industry: Life Sciences 
Sector: Life Sciences 
Pages: 35 

Reasons to buy this report

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
 

Arix Bioscience PLC (ARIX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Report 05IC-GDPH2525080D has a rating of 85 percent
Figure of merit assessment for report 05IC-GDPH2525080D

Relevance Rating

The Research and Experts relevance ranting consists of a set of figure of merit (FOM) values that are provided as an indication of the value of the report in the current economic environment.

These FOM values cannot take into account the reason for the clients interest in a report and therefore the client should view these FOM values only as a visual guide. The FOM scores are based on

market interest - how often the report is viewed or purchased,
elapsed time - time since the report was published,
report detail - amount of detail in the report (pages, figures, images, comments etc.) and
price - the price of the report.


Regional Information

Taxonomy

Branch ID: 1408

Taxonomy Location

The taxonomy on the left shows the ancestors of the United Kingdom node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

United Kingdom

The UK economy is the second largest in the eurozone. Almost every industrial sector is well established in the UK and those worth mentioning include Aerospace, Agriculture, Automotive, Business and professional services, Chemicals, Construction, Consumer goods, Defence equipment, Education, Electronics, Energy, Entertainment, Financial services, Food and beverages, Healthcare, Hospitality and leisure, Industrial equipment, Information technology, Media, Pharmaceuticals and biotechnology, Processed metals, Real estate, Retailing, Scientific equipment, Telecommunications, Tourism, Transportation and logistics, Utilities.

The UK is emerging from recession in the Eurozone with growth in manufacturing and construction. The National Institute for Economic and Social Research is predicting growth of 2.5% in 2014 and 2.1% in 2015. Some economists predict that growth could reach 3% if inflation is properly managed. Unemployment is expected to fall to 6.5 -7% in 2014. Interest rates will remain low and inflation should remain around 2%.

Growth in 2013 was helped by a boost in consumer spending but that will not continue without an increase in wages and a higher debt-to-income ratio in the future.

The manufacturing and construction sectors are still not as strong as they should be and further investments in these sectors is required. 

One of the issues that businesses in the UK are keen to address is productivity and many companies are holding off on hiring and pay increases until this issue is tackled. 

David Cameron is keen to push more 'reshoring' of jobs in the manufacturing sector and 2013 saw over 1,500 jobs return to the UK in the automobile, clothing, manufacturing and other industries. The provision of cheaper energy including nuclear and 'shale gas' is seen as paramount to increased job creation.

Other challenges in the British economy include an aging population, youth unemployment, an inflexible labour market and competing with the US on energy costs. The US has the advantage of shale gas which is three times cheaper than British gas.

In an effort to increase competitiveness the conservative government is investing £375billion in energy, transport, communications and water over the next 5 years. This will be matched by £25billion from the insurance industry. Taxes have been cut and welfare has undergone reform. There are generous tax incentives for investors in start-up companies. All these efforts should go a long way towards driving growth in the UK.

Researchandexperts.com is a  leading source of market research on the UK.

Useful Links

World Bank Overview of the United Kingdom

CIA World Factbook on UK

National Institute for Economic and Social Research (UK)

UK Trade and Investment

United Kingdom

British Islands

Region

 

Europe

Fifty six sovereign states are listed with territory in Europe (six have limited rocognition). The 50 soverign states of Europe are Albania, Andorra, Armenia, Austria, Azerbaijan, Belarus, Belgium, Bosnia & Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark,  Estonia,  Finland, France, Georgia, Germany, Greece, Hungary, Iceland, Ireland, Italy, Kosovo, Latvia, Lithuania, Luxembourg, Macedonia, Malta, Moldova, Monaco, Montenegro, The Netherlands, Norway, Poland, Portugal, Romania, Russia, San Marino, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, Ukraine, United Kingdom, Vatican City (Holy See).

The leading economies of Europe are Germany, France, UK, Italy and Russia.
 
Research and Experts, the market intelligence platform, provides companies with access to the latest leading industry reports covering the European region. Our company reports contain the following information; company overviews, key facts, key employees, products and services, as well as financial ratios. Our industry reports are vital sources of detailed historic and forecast values for markets in Europe, segmented at category level. Research and Experts reports also provide regional analysis and analysis of the leading companies in key European markets. 

Europe

Country

Countries

 

Industry Sector Information

Taxonomy

Branch ID: 205

Taxonomy Location

The taxonomy on the left shows the ancestors of the Life Sciences node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

Life Sciences

The Life Sciences industry includes biotechnology, healthcare, pharmaceuticals, medical devices and diagnostics. The industry is dominated by US companies requiring considerable investment in research and development to stay competitive.  While US companies dominate this space, competition is emerging from smaller companies in Europe and Asia. 

Companies trying to stay competitive or enter new markets in life sciences consult our reports. For example, Plimsoll, in their recent review of global antibiotic manufacturers have reviewed 150 of the largest manufacturers including analysis of  ANTIBIOTICE SA, BAYER HEALTHCARE MANUFACTURING SRL and CIPLA LTD. 

Our reports are a requirement for companies looking for the best competitive intelligence in the life sciences sector providing information on market size, rankings, best trading partners and financial analysis. 

Useful Links

Analytical Life Sciences and Diagnostics Association

German Life Sciences Association

 

Life Sciences

Industry

Industries

 

 

Buy: Arix Bioscience PLC (ARIX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

 

Item Code: 05IC-GDPH2525080D

 
Licence: Single User
Price: $250.00
 
VAT: 0.0% 
Total: $250.00 

Feedback

Return to Research and Experts

Page created and rendered - Cache updated [0.13398s]

--